Tissue | Expression Dynamics | Abbreviation |
Cervix | | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions |
N_HPV: HPV-infected normal cervix |
Esophagus | | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Oral Cavity | | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Skin | | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00085446 | Cervix | CC | epidermis development | 83/2311 | 324/18723 | 3.91e-11 | 8.54e-09 | 83 |
GO:00435884 | Cervix | CC | skin development | 71/2311 | 263/18723 | 8.04e-11 | 1.46e-08 | 71 |
GO:00506737 | Cervix | CC | epithelial cell proliferation | 98/2311 | 437/18723 | 2.01e-09 | 2.15e-07 | 98 |
GO:003367410 | Cervix | CC | positive regulation of kinase activity | 101/2311 | 467/18723 | 8.66e-09 | 7.22e-07 | 101 |
GO:00302164 | Cervix | CC | keratinocyte differentiation | 42/2311 | 139/18723 | 1.74e-08 | 1.28e-06 | 42 |
GO:00099137 | Cervix | CC | epidermal cell differentiation | 53/2311 | 202/18723 | 5.48e-08 | 3.25e-06 | 53 |
GO:00458608 | Cervix | CC | positive regulation of protein kinase activity | 85/2311 | 386/18723 | 5.61e-08 | 3.29e-06 | 85 |
GO:00075689 | Cervix | CC | aging | 75/2311 | 339/18723 | 2.75e-07 | 1.13e-05 | 75 |
GO:00018908 | Cervix | CC | placenta development | 40/2311 | 144/18723 | 4.59e-07 | 1.77e-05 | 40 |
GO:19030349 | Cervix | CC | regulation of response to wounding | 44/2311 | 167/18723 | 6.33e-07 | 2.31e-05 | 44 |
GO:00310988 | Cervix | CC | stress-activated protein kinase signaling cascade | 58/2311 | 247/18723 | 8.02e-07 | 2.89e-05 | 58 |
GO:00614588 | Cervix | CC | reproductive system development | 87/2311 | 427/18723 | 1.37e-06 | 4.55e-05 | 87 |
GO:00486088 | Cervix | CC | reproductive structure development | 86/2311 | 424/18723 | 1.90e-06 | 5.97e-05 | 86 |
GO:00719007 | Cervix | CC | regulation of protein serine/threonine kinase activity | 75/2311 | 359/18723 | 2.76e-06 | 8.02e-05 | 75 |
GO:00514038 | Cervix | CC | stress-activated MAPK cascade | 55/2311 | 239/18723 | 2.96e-06 | 8.31e-05 | 55 |
GO:00323868 | Cervix | CC | regulation of intracellular transport | 71/2311 | 337/18723 | 3.70e-06 | 9.74e-05 | 71 |
GO:00109757 | Cervix | CC | regulation of neuron projection development | 88/2311 | 445/18723 | 4.26e-06 | 1.09e-04 | 88 |
GO:00107206 | Cervix | CC | positive regulation of cell development | 64/2311 | 298/18723 | 5.69e-06 | 1.41e-04 | 64 |
GO:00703027 | Cervix | CC | regulation of stress-activated protein kinase signaling cascade | 46/2311 | 195/18723 | 9.35e-06 | 2.11e-04 | 46 |
GO:00313467 | Cervix | CC | positive regulation of cell projection organization | 72/2311 | 353/18723 | 1.04e-05 | 2.32e-04 | 72 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
MAP2K1 | SNV | Missense_Mutation | novel | c.12G>T | p.Lys4Asn | p.K4N | Q02750 | protein_coding | deleterious(0.01) | benign(0.135) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
MAP2K1 | SNV | Missense_Mutation | | c.256N>G | p.Ser86Ala | p.S86A | Q02750 | protein_coding | tolerated(0.67) | benign(0.027) | TCGA-D8-A1XK-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicine+cyclophosphamide | SD |
MAP2K1 | SNV | Missense_Mutation | | c.607N>A | p.Glu203Lys | p.E203K | Q02750 | protein_coding | deleterious(0) | possibly_damaging(0.838) | TCGA-E2-A159-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | SD |
MAP2K1 | SNV | Missense_Mutation | rs754765552 | c.1006G>C | p.Asp336His | p.D336H | Q02750 | protein_coding | deleterious(0.03) | possibly_damaging(0.897) | TCGA-PE-A5DE-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxotere | CR |
MAP2K1 | insertion | Frame_Shift_Ins | novel | c.845_846insCCCAGGCTGGAGTGCAGTGGTGCGATCT | p.Ala283ProfsTer12 | p.A283Pfs*12 | Q02750 | protein_coding | | | TCGA-A2-A0EM-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | tamoxiphen | SD |
MAP2K1 | SNV | Missense_Mutation | novel | c.770N>T | p.Ala257Val | p.A257V | Q02750 | protein_coding | tolerated(0.11) | benign(0.274) | TCGA-EA-A3HS-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
MAP2K1 | SNV | Missense_Mutation | | c.1046N>A | p.Arg349Lys | p.R349K | Q02750 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-EK-A2RA-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Unknown | Unknown | SD |
MAP2K1 | SNV | Missense_Mutation | | c.1099N>C | p.Glu367Gln | p.E367Q | Q02750 | protein_coding | tolerated(0.07) | benign(0.062) | TCGA-VS-A94Z-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
MAP2K1 | SNV | Missense_Mutation | | c.308N>A | p.Ile103Asn | p.I103N | Q02750 | protein_coding | deleterious(0) | possibly_damaging(0.866) | TCGA-VS-A9UQ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | PD |
MAP2K1 | SNV | Missense_Mutation | | c.692N>T | p.Ser231Leu | p.S231L | Q02750 | protein_coding | deleterious(0) | possibly_damaging(0.871) | TCGA-A6-5661-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
5604 | MAP2K1 | ENZYME, DRUGGABLE GENOME, KINASE, CLINICALLY ACTIONABLE, SERINE THREONINE KINASE, DRUG RESISTANCE, TYROSINE KINASE, NUCLEAR HORMONE RECEPTOR | | SELUMETINIB | SELUMETINIB | |
5604 | MAP2K1 | ENZYME, DRUGGABLE GENOME, KINASE, CLINICALLY ACTIONABLE, SERINE THREONINE KINASE, DRUG RESISTANCE, TYROSINE KINASE, NUCLEAR HORMONE RECEPTOR | | WX-554 | WX-554 | |
5604 | MAP2K1 | ENZYME, DRUGGABLE GENOME, KINASE, CLINICALLY ACTIONABLE, SERINE THREONINE KINASE, DRUG RESISTANCE, TYROSINE KINASE, NUCLEAR HORMONE RECEPTOR | | Pyridic ketone derivative 1 | | |
5604 | MAP2K1 | ENZYME, DRUGGABLE GENOME, KINASE, CLINICALLY ACTIONABLE, SERINE THREONINE KINASE, DRUG RESISTANCE, TYROSINE KINASE, NUCLEAR HORMONE RECEPTOR | | PANITUMUMAB | PANITUMUMAB | 31227518 |
5604 | MAP2K1 | ENZYME, DRUGGABLE GENOME, KINASE, CLINICALLY ACTIONABLE, SERINE THREONINE KINASE, DRUG RESISTANCE, TYROSINE KINASE, NUCLEAR HORMONE RECEPTOR | allosteric modulator | 363894205 | TAK-733 | |
5604 | MAP2K1 | ENZYME, DRUGGABLE GENOME, KINASE, CLINICALLY ACTIONABLE, SERINE THREONINE KINASE, DRUG RESISTANCE, TYROSINE KINASE, NUCLEAR HORMONE RECEPTOR | allosteric modulator | 249565604 | BINIMETINIB | |
5604 | MAP2K1 | ENZYME, DRUGGABLE GENOME, KINASE, CLINICALLY ACTIONABLE, SERINE THREONINE KINASE, DRUG RESISTANCE, TYROSINE KINASE, NUCLEAR HORMONE RECEPTOR | | BAY 869766 | | |
5604 | MAP2K1 | ENZYME, DRUGGABLE GENOME, KINASE, CLINICALLY ACTIONABLE, SERINE THREONINE KINASE, DRUG RESISTANCE, TYROSINE KINASE, NUCLEAR HORMONE RECEPTOR | inhibitor | PIMASERTIB | PIMASERTIB | |
5604 | MAP2K1 | ENZYME, DRUGGABLE GENOME, KINASE, CLINICALLY ACTIONABLE, SERINE THREONINE KINASE, DRUG RESISTANCE, TYROSINE KINASE, NUCLEAR HORMONE RECEPTOR | inhibitor | CHEMBL2146883 | COBIMETINIB | |
5604 | MAP2K1 | ENZYME, DRUGGABLE GENOME, KINASE, CLINICALLY ACTIONABLE, SERINE THREONINE KINASE, DRUG RESISTANCE, TYROSINE KINASE, NUCLEAR HORMONE RECEPTOR | | VEMURAFENIB | VEMURAFENIB | 22197931,7651428,18632602,19915144,23569304,25157968 |